Jones Report is very goodI had a chance to look at it more closely and it is the best report ever done on TH in my opinion. Very strong info and analysis on the cancer side of the equation which is all important. Great, very comprehensive work on the financial statement projections out to 2030 and good valuation analysis. Who would have thought the retail broker would put out the best report on TH? Not me.
He is projecting share issuance of $50 million in 2023, $50 million in 2024 and $100 million in 2025, likely to go along with clinical success with TH-1902.
I am not sure how things work with these retail brokers but there was obviously no immediate reaction to this excellent report by the market. If they are able to get their clients engaged with the stock, however, it could have a big impact.